cassava7
Senior Member (Voting Rights)
Access to individual patient-level data (IPD) of randomized clinical trials (RCTs) increases the reproducibility of research, facilitates exploration of effect modifiers, and leverages research investments beyond the original research question.
This study aimed to describe access to IPD of RCTs of pharmacological treatments for COVID-19 and to determine whether the intent to share IPD as reported in the registry and publication or preprint was consistent with actual access to IPD.
JAMA - https://jamanetwork.com/journals/jama/fullarticle/2803583
—
Summary by epidemiologist Gideon Meyerowitz-Katz:
Interesting paper - of 224 COVID-19 RCTs preprinted or published by May 2021, only 22% had accessible patient data on request
Studies done in high-income countries, with mixed funding, with more patients, and preprints were more likely to provide data on request
Data availability statements were, on the whole, untrue. Of the 138 RCTs that said they would share data, only 37 (27%) actually sent it through after a request and multiple reminders
This study aimed to describe access to IPD of RCTs of pharmacological treatments for COVID-19 and to determine whether the intent to share IPD as reported in the registry and publication or preprint was consistent with actual access to IPD.
JAMA - https://jamanetwork.com/journals/jama/fullarticle/2803583
—
Summary by epidemiologist Gideon Meyerowitz-Katz:
Interesting paper - of 224 COVID-19 RCTs preprinted or published by May 2021, only 22% had accessible patient data on request
Studies done in high-income countries, with mixed funding, with more patients, and preprints were more likely to provide data on request
Data availability statements were, on the whole, untrue. Of the 138 RCTs that said they would share data, only 37 (27%) actually sent it through after a request and multiple reminders